NEWS
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
IGC Pharma (NYSE American: IGC) has announced promising preclinical research on IGC-1C, a novel small-molecule modulator. The findings reveal that IGC-1C targets tau protein phase separation, offering new possibilities for treating neurodegenerative diseases.
IGC Pharma (NYSE American: IGC) has announced promising preclinical research on IGC-1C, a novel small-molecule modulator. The findings reveal that IGC-1C targets tau protein phase separation, offering new possibilities for treating neurodegenerative diseases.
Additionally, IGC-1C has been identified as a potential GLP-1 receptor agonist, showing promise for weight loss treatments and presenting a unique strategy to combat Alzheimer's disease.
Key points:
▪️IGC-1C exhibits a dissociation constant (Kd) of 3.95 ± 0.32 μM with tau, indicating strong binding affinity
▪️The molecule effectively inhibits tau condensates and prevents their transition into toxic fibrils
IGC-1C's dual action targets both tau and GLP-1 receptors, potentially addressing multiple pathways in Alzheimer's and metabolic disorders
The company aims to advance IGC-1C through future clinical trials
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2879Followers
108Following
30KVisitors
Follow